COVID vaccine trials lack important study participants
ATLANTA — Gwinnett County Transit driver Mikesha Walker talked to co-workers recently about whether they would participate in a COVID-19 vaccine research trial.They’re ideal participants, many researchers say. They spend more time with the public, which puts them at greater exposure to the disease. Many workers are Black, a demographic that is not adequately represented in trials.However, Walker said the drivers are very reluctant to participate. Many feel underappreciated and underpaid for continuing to work during the pandemic. They’re also aware of health studies done decades ago, such as t...
The Atlanta Journal-Constitution
Researchers working on COVID-19 antibody trial
MINNEAPOLIS — The federal government has tapped researchers at the University of Minnesota to oversee international clinical trials of synthetic antibody therapies, and whether they can treat COVID-19.The goal is to harness the natural power of antibodies, produced by the immune system in response to infections, and to mass produce it against an infectious disease in COVID-19 for which there are few proven treatments.“This has been considered the highest priority study by the NIH,” said James Neaton, the U biostatistics professor who is leading the research.Neaton’s INSIGHT network was selecte...
Star Tribune (Minneapolis)
COVID-19 vaccine trial kicks off in Florida, with volunteers getting up to $1,000
FORT LAUDERDALE, Fla. — Another major clinical trial is underway in the global race for a COVID-19 vaccine — with researchers this time planning to pay participants hundreds of dollars in Palm Beach County.The experimental vaccine, called AZD1222, was developed by AstraZeneca in conjunction with the University of Oxford. The drug arrived Monday morning to the campus of the JFK Medical Center in Atlantis, and the first 10 patients for the study will start the process Tuesday morning. The vaccine is one of just five that are in the crucial stage of Phase 3 testing, according to Dr. Larry Bush, l...
COVID-19 clinical trials lack diversity, study says
Although people of color have disproportionately been diagnosed with COVID-19, they are underrepresented in clinical trials, according to a study released by a team of researchers from the universities of Georgia, Colorado and Phoebe Putney Memorial Hospital in Albany.In a federally-funded trial that is testing the efficacy of the antiviral remdesivir, Black Americans accounted for 20% of the total patient population, the researchers found. In the Gilead-funded clinical trial of the drug, about one out of every 10 patients given remdesivir were Black. Latinx and Native Americans comprised 23% ...
The Atlanta Journal-Constitution
Nation and world news briefs
1 in 3 Americans would refuse COVID-19 vaccine, new Gallup poll findsOne in 3 Americans would refuse an FDA-approved coronavirus vaccine even if it were offered at no cost, a new Gallup poll released Friday found.The results, based on survey conducted between July 20 and Aug. 2, found that 65% of respondents said they would accept the offer and get themselves vaccinated while 35% said they would not.The new poll falls in line with previous Gallup findings suggesting political party preference plays a strong role in Americans’ views on COVID-19.Eighty-one% of Democrats would be willing to get v...
Tribune News Service
In search for COVID-19 treatments, consumer group pushes drugmaker Gilead to test alternative to remdesivir
The pharmaceutical company that makes remdesivir — the only medication that has emergency authorization to fight COVID-19 — should also be conducting human trials on a related drug with strong potential, according to a citizen advocacy group that believes the alternative could be more effective, less expensive and easier to produce.Washington, D.C.-based Public Citizen sent a letter dated Tuesday to the CEO of Gilead Sciences and top federal regulators, urging the company and the government to work together to move forward with clinical trials of the drug “or publicly provide evidence why it i...
Study: Antiviral drug remdesivir helps white, Black and Latino patients equally
CHICAGO — Remdesivir, the only drug given emergency approval for treatment of COVID-19, appears to provide equal benefits to white, Asian, Black and Latino patients, according to an analysis led by researchers at University of Chicago Medicine.It’s encouraging news, infectious disease experts say, because of the disparate effects of the disease on different groups. Black people are dying at higher rates than people of other races, and Latinos are contracting the disease at higher rates than others.Dr. Kathleen Mullane, a UChicago Medicine infectious disease expert, said the results — which wer...
Hydroxychloroquine is the most disappointing, disavowed drug that researchers keep studying for COVID-19
Barely three months ago, the anti-malarial drug that President Donald Trump touted seemed like such a sure bet against COVID-19 that Susanna Naggie had a tough time setting up a national clinical trial comparing it to placebo. Colleagues said giving a fake pill would be unethical since the real thing might save lives.Now, hydroxychloroquine, or HCQ, has fallen into such disfavor that healthcare workers are leery of Naggie’s trial. Called HERO (a loose acronym for HEalth Care Worker pROphylaxis Against COVID-19) it is designed to see if the drug can protect them from infection.“Our original rec...
The Philadelphia Inquirer
Moderna delays Phase 3 trial for COVID-19 vaccine
Moderna’s heavily anticipated trial for a coronavirus vaccine, which was set to begin next week, has been delayed.“Moderna has previously disclosed that the Phase 3 trial of its COVID-19 vaccine candidate mRNA-1273 is expected to begin in July. The trial is still expected to begin in July and we expect to be the first to start a Phase 3 trial,” read a company statement sent to The New York Daily News Thursday. “We have worked closely with NIH/OWS to align on the final protocol in order to begin the trial on time.”The Phase 3 study, which includes 30,000 patients, was initially supposed to begi...
New York Daily News